YieldMax MRNA Option Income Strategy ETF (MRNY)

The long-term rating is severely compromised by a catastrophic -82% collapse over the last year, which serves as undeniable proof of structural failure rather than a temporary correction. While the current price sits near the 52-week low, the asset is a classic value trap: the market has correctly priced in the inability of this option-income strategy to sustain its previous performance. The recent price action shows a volatile recovery attempt, but the sheer magnitude of the prior decline indicates the underlying business model or the specific underlying stock dynamics have broken down. The dividend yield of nearly 40% is a dangerous illusion; it represents a massive erosion of capital value, not sustainable income. Investors are buying the dip, but the options data confirms their fear, with a dense wall of put orders waiting to catch any further falls. This is not a turnaround story; it is a distressed asset where the principal has been largely destroyed.